Figures computed from official regulatory filings — .
Analysttarget 4.75 USD (+221%) · consensus 4.4/5 · 4 buy · 1 hold · 0 sell
Ownershipinsiders 8.14% · institutions 87.42% · short 16.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Century Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
7 buys63 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Russotti Gregory | Sell | $5K | SEC |
| Pfeiffenberger Brent | Other | $26.9K | SEC |
| Carr Douglas | Sell | $3.2K | SEC |
| Truitt Joseph | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Russotti Gregory | Sell | $1.1K | SEC |
| Pfeiffenberger Brent | Other | $976.9 | SEC |
| Carr Douglas | Sell | $520.7 | SEC |
| Pfeiffenberger Brent | Other | $59.9K | SEC |
| Carr Douglas | Sell | $543.7 | SEC |
| Carr Douglas | Sell | $3.7K | SEC |
| Pfeiffenberger Brent | Other | $31K | SEC |
| Russotti Gregory | Sell | $5.8K | SEC |
| Cowan Chad | Other | $801.9 | SEC |
| Lee Han Myung | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quimi Daphnetrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blackwell Kimberly | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Riva Alessandro | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Murphy Martin Patrick | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pfeiffenberger Brent | Other | $986.2 | SEC |
| Carr Douglas | Sell | $525.6 | SEC |
| Russotti Gregory | Sell | $1.1K | SEC |
| Pfeiffenberger Brent | Other | $72.9K | SEC |
| Carr Douglas | Sell | $618 | SEC |
| Murphy Martin Patrick | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cowan Chad | Other | $3K | SEC |